Personalized Medicine: Getting More Out of Clinical Trials
February 15, 2019
IDDI in Contract Pharma Magazine
IDDI, BMS Consortium aims to establish that the GPC statistical method can complement the design, analysis and interpretation of clinical trial results;
Kristin Brooks, Contract Pharma 02.15.19
IDDI recently initiated collaborative research on a statistical method for individualization of therapy. The goal is to establish proof of the concept that the GPC method can complement traditional methods for the design, analysis and interpretation of clinical trial results. The research will be carried out by a Consortium led by IDDI and comprising Bristol-Myers Squibb, the European Organization for Research and Treatment of Cancer (EORTC), the Université Catholique de Louvain (UCLouvain) and the University Hospital and Cancer Center of Lyon.
Contract Pharma spoke with Marc Buyse, founder of IDDI, and Everardo Saad, medical director of IDDI, about the goals of the new collaboration, the shortcomings of current methods in clinical trials and how new statistical methods can be used to improve outcomes. –KB